Compare TOVX & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOVX | AIMD |
|---|---|---|
| Founded | 2001 | 1984 |
| Country | United States | United States |
| Employees | N/A | 41 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 11.5M |
| IPO Year | 2012 | N/A |
| Metric | TOVX | AIMD |
|---|---|---|
| Price | $0.23 | $1.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 403.4K | 40.3K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $1.26 |
| 52 Week High | $0.86 | $4.44 |
| Indicator | TOVX | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 43.35 |
| Support Level | $0.22 | $1.35 |
| Resistance Level | $0.26 | $1.75 |
| Average True Range (ATR) | 0.01 | 0.14 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 72.05 | 51.36 |
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.